ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Test Product HYP-6589

A development code.

Its studies are led by Sichuan Huiyu Pharmaceutical.

Furthest: phase 2, since Nov 26, 20241 company-led study, 1 open or runningNext primary completion: Apr 10, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sichuan Huiyu Pharmaceutical11 open or runningphase 2since Nov 26, 2024Nov 26, 2024Apr 10, 2028phase 2 · NCT06712680

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 26, 2024First study: phase 2 study in Solid TumorFirst studyNCT06712680 · 115 planned · China

Ahead

  1. Apr 10, 2028Primary completion: phase 2 study in Solid TumorNCT06712680

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06712680Solid Tumor · China2RecruitingApr 10, 2028115

How it is read

Names in the registry

  • “Test Product HYP-6589”, 1 entry

Codes read as this program: HYP6589.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.